German Medical Cannabis Sales may Top €420 million
Following the passing of the CanG Act and the linked MedCanG Act, the German medical cannabis market is encountering significant growth, with medical cannabis sales in Germany anticipated to get above €420 million in 2024, rising to over €1 billion in 2028.
This forecast, published in Prohibition Partners' The German Cannabis Report, is founded on several elements, including removing cannabis from Germany's narcotics list and eradicating previous tie-ups related to handling, allocation, dispensing and prescribing. This is, partly pushing the growth in patient populations, prescription rates and the rise of telemedicine operators for medical cannabis.
Additionally, the BfArM (Federal Institute for Drugs and Medical Devices) has cancelled the tendering procedure for home growing of medical cannabis, permitting new growers to apply for licenses to grow in the country, and opening up the industry to more competition.
Doctors in Germany can freely prescribe medical cannabis for any requirement they believe can greatly help their patients. Additionally, recent policy changes, like removing cannabis from the narcotics list, are anticipated to improve patient access further.
How Much Medical Cannabis Does Germany Sell?
The amount of medical cannabis that is sold in pharmacies soared by roughly 30% in the third quarter of 2023 compared to the same period in 2022. The number of patients rose even more noticeably after the enactment of new cannabis laws in April 2024.
In Germany, there is a designated repayment framework for medical cannabis treatments by statutory health insurance companies. This public support made up about half of the market until 2023.
In July 2024, the Federal Joint Committee (G-BA) assumed proposals to facilitate the reimbursement procedure, which are anticipated to make access even easier for patients as medical cannabis becomes cheaper.
The removal of the tendering process has opened up the market to competition which will likely lead to a rise in domestic production ultimately reducing Germany's reliance on imports. However, following the passing of the CanG law, imports of medical cannabis rose remarkably by 44%, attaining a high of 11,706 kilograms in the second quarter of 2024 in comparison to 8,143 kilograms in the first quarter of 2024.
The recent legislation in Germany celebrates a new age in the European cannabis industry in Europe. This is a critical opportunity for innovation, economic growth and responsible regulation for all of us in the industry. With Germany currently being the primary player in changing the view of the cannabis industry in Europe, they have the chance to set the standards for sustainable methods and benchmarks.
More From Soft Secrets:
Is German Cannabis Reform Under Threat?